The role of bone sialoprotein in bone metastasis

Conference (1999)

Galectin-1 Expression in Prostate Tumor-Associated Capillary Endothelial Cells Is Increased by Prostate Carcinoma Cells and Modulates Heterotypic Cell-Cell Adhesion

in Angiogenesis (1999), 3(4), 317-25

Besides providing tumors with nutrients, newly formed capillaries constitute a potential escape route for tumor cells favoring metastatic dissemination, and constitute an access for the anti-tumoral host ... [more ▼]

Besides providing tumors with nutrients, newly formed capillaries constitute a potential escape route for tumor cells favoring metastatic dissemination, and constitute an access for the anti-tumoral host immune cells. Galectin-1, a soluble human lectin, is involved in numerous biological functions including cell-cell and cell-substrate interactions. In addition, galectin-1 is able to induce apoptosis of activated T-lymphocytes. In this study, we have examined galectin-1 expression in capillaries associated to the carcinoma cells or present in the remote non-tumoral stroma of 100 human prostate carcinoma samples by immunoperoxidase staining. Galectin-1 was expressed by endothelial cells from capillaries infiltrating the tumor tissue in 64% (64/100) of the cases. On the contrary, endothelial cells in the adjacent non-tumoral stroma expressed galectin-1 in very few cases (7/100). Increased frequency of galectin-1-positive capillaries in the tumor-associated compared to the tumor-free areas was observed in 63% of the cases. This striking contrast led us to set up an in vitro model to test whether tumor cells could induce galectin-1 expression by endothelial cells. Incubation of human umbilical vein endothelial cells with conditioned media from PC-3 or DU 145 prostate carcinoma cells led to a significant increase of galectin-1 protein expression (+32.97% and 37.91% P < 0.01 and P < 0.05, respectively). PC-3 conditioned medium also induced increased adhesion values of PC-3 cells to the endothelial cells (53.4 +/- 4.7 vs. 38.5 +/- 3.5 after 30 min; 66.6 +/- 7.8 vs. 46.2 +/- 6.4 after 60 min). An anti-galectin-1 antiserum abolished this modulation, and recombinant galectin-1 also induced increased adhesion values in a dose-dependent fashion. This effect was specific as no such modulations were observed using normal lymphocytes instead of PC-3 cells. Preferential galectin-1 expression in the endothelial cells close to the cancer cells could provide these latter with increased abilities to interact with the endothelial cells as well as a defense against the host immune system. [less ▲]

Prognostic Value of Bone Sialoprotein Expression in Clinically Localized Human Prostate Cancer

in Journal of the National Cancer Institute (1998), 90(13), 1000-8

BACKGROUND: Bone sialoprotein (BSP), a bone matrix protein, was recently found to be expressed ectopically in breast cancer and to have a statistically significant association with poor prognosis and the ... [more ▼]

BACKGROUND: Bone sialoprotein (BSP), a bone matrix protein, was recently found to be expressed ectopically in breast cancer and to have a statistically significant association with poor prognosis and the development of bone metastases in that disease. These data prompted us to investigate whether BSP might also be expressed in human prostate cancer, which often metastasizes to bone, and be predictive for progression risk. METHODS: Tissue sections from 180 patients who had undergone a radical prostatectomy for localized prostate cancer were analyzed immunohistochemically for BSP expression. Biochemical progression was defined as an increasing serum prostate-specific antigen level of 0.5 ng/mL or more. Statistical analysis was used to assess associations between pathologic findings and level of BSP expression, and a Cox proportional hazards model was used to determine which clinical and histologic parameters, including stage, Gleason score, and BSP expression (immunostaining intensity and extent), were independently associated with biochemical progression. All P values were two-sided. RESULTS: Most of the prostate cancer lesions examined (78.9%) expressed detectable levels of BSP, compared with no or low expression in the adjacent normal glandular tissue. A statistically significant association was found between BSP expression and biochemical progression in both univariate and multivariate analyses. After a follow-up interval of 3 years, the biochemical relapse rate was 36.7% (95% confidence interval [CI] = 23.4%-47.7%) in patients whose tumors expressed high levels of BSP compared with 12.1% (95% CI = 2.3%-20.8%) in patients whose tumors expressed no or a low detectable level of the protein (logrank test, P = .0014). BSP expression status could identify those patients at higher risk of biochemical progression (logrank test, P<.05) among patients with moderately differentiated tumors or with pathologically confined tumors. CONCLUSIONS: To our knowledge, this study is the first to demonstrate BSP expression in human prostate cancer and to highlight the protein's statistically significant prognostic value in patients with clinically confined prostate adenocarcinomas. [less ▲]

Expression of bone sialoprotein in human prostate cancer is associated with progression

in Acta Clinica Belgica (1998, January), 53(3), 221-240

Detection of bone sialoprotein in primary and metastatic lesions of human breast and prostate carcinomas, the two major osteotropic cancers

in Revue du Rhumatisme (English ed.) (1998), 7-9

Independent value of the 67-kilodalton laminin receptor in human prostate cancer

Conference (1997, January 17)

Overexpression of the 67-kD laminin receptor correlates with tumor progression in human prostate cancer

in Proceedings of the American Association for Cancer Research (1997), 38

Independent value of the 67-kilodalton laminin receptor in human prostate cancer

in Acta Clinica Belgica (1997), 52(2), 93

Overexpression of the 67-kDa laminin receptor correlates with tumor progression in human prostate cancer

in Clinical & Experimental Metastasis (1996, March), 14(Suppl. 1), 1996

Exploration du testicule cryptorchide non palpe

in Acta Urologica Belgica (1995), 63(2), 69-76

Cryptorchidism affects approximately 1 in 150 boys. Non-palpable testes represent nearly 20% of all cases. If present, they are situated between the inferior renal pole and the external inguinal ring ... [more ▼]

Cryptorchidism affects approximately 1 in 150 boys. Non-palpable testes represent nearly 20% of all cases. If present, they are situated between the inferior renal pole and the external inguinal ring. Often at surgical exploration, however, a "nubbin" of testicular tissue is found at the end of blind ending spermatic vessels without demonstration of a recognizable testis; this finding is referred to as an absent testis. In other patients, no vascular or ductular (epididymis-vas deferens) or even testicular structure can be observed. This situation defines true testicular agenesis. Non-palpable testes have an increased risk of malignant transformation, infertility, associated inguinal hernia and congenital ductular abnormalities. Surgical treatment is often more complex and unsuccessful. Many imaging diagnostic methods to investigate patients with non-palpable testes (pneumoperitoneography, angiography, ultrasonography, CT scan and RMN) have been used so far but none of these has been uniformly accepted as the ideal investigative technique because they are unreliable and/or they involve a fair risk. Since Cortesi and associates first described in 1976 a case of abdominal testes identified by laparoscopy, this technique has gained increased acceptance by pediatric urologists and surgeons. Today, celioscopy plays a central role in the exploration of non-palpable cryptorchid testes. The authors try to establish an algorithm methodology for investigating non-palpable testes under the light of recently reported anatomical, pathological and surgical data. [less ▲]